Mark Epstein
Neurology with Special Qualifications in Child Neurology · Weston, FLNPI 1376613430
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,079 of the $64,066 with a category attached, or 79.7%. Supernus Pharmaceuticals, Inc. accounts for 71.1% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2022 at $19,815 and has fallen 97.5% since, to $496 in 2025. Among neurology with special qualifications in child neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $182.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$46K
- Neurelis, Inc.$11K
- Livanova USA, Inc.$3K
- UCB, Inc.$976
- Aquestive Therapeutics, Inc.$659
- Jazz Pharmaceuticals Inc.$566
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$51,07980%
- Travel & lodging$5,0578%
- Food & beverage$7,93012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 84 | $45,551 |
| Neurelis, Inc. | 29 | $10,855 |
| Livanova USA, Inc. | 20 | $3,018 |
| UCB, Inc. | 32 | $976 |
| Aquestive Therapeutics, Inc. | 32 | $659 |
| Jazz Pharmaceuticals Inc. | 26 | $566 |
| Corium, LLC | 20 | $370 |
| Eisai Inc. | 13 | $242 |
| Tris Pharma Inc | 12 | $211 |
| Greenwich Biosciences, Inc. | 12 | $203 |
| Sunovion Pharmaceuticals Inc. | 10 | $170 |
| Sumitomo Pharma America, Inc. | 6 | $157 |
| Catalyst Pharmaceuticals, Inc. | 7 | $152 |
| Ironshore Pharmaceuticals Inc. | 9 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $109 |
| Novartis | 7 | $106 |
| AbbVie | 4 | $98 |
| Neos Therapeutics, LP | 5 | $95 |
| Aprecia Pharmaceuticals, LLC | 3 | $57 |
| SK Life Science, Inc. | 2 | $49 |
| Tepha Inc | 1 | $46 |
| Aucta Pharmaceuticals, Inc. | 2 | $42 |
| Upsher-smith Laboratories LLC | 2 | $39 |
| Cranial Technologies, Inc | 2 | $30 |
| Biocodex, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$41,324
- VALTOCO$10,290
- VNS Therapy$2,775
- SYMPAZAN$122
How this compares
$64,066 in reported general payments places this provider in the 90th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Other neurology with special qualifications in child neurology in Weston
- Paul WinnerWest Palm Beach$624K
- Omer Abdul HamidOrlando$283K
- Natalie GillsonFort Myers$250K
- Trevor ResnickMiami$230K
- Migvis MonduyMiami$188K
- Elza VasconcellosMiami$170K
- Ronald DavisWinter Park$154K
- Ian MillerMiami$104K
- Michael HammerSaint Petersburg$100K
- Matt LallasMiami$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.